100896-16-0

Basic information

• Product Name: 2,3,5-tri-O-benzyl-D-xylitol
• Synonyms: 2,3,5-tri-O-benzyl-D-xylitol
• CAS NO: 100896-16-0
• Molecular Weight: 422.521
• Mol File: 100896-16-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2,3,5-tri-O-benzyl-D-xylitol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,5-tri-O-benzyl-D-xylitol(100896-16-0)
• EPA Substance Registry System: 2,3,5-tri-O-benzyl-D-xylitol(100896-16-0)

Safety Data

• Hazardous Substances Data: 100896-16-0(Hazardous Substances Data)

Upstream product

• 58-86-6 D-xylose 
• 79083-38-8 1-O-methyl 3,5-di-O-benzyl α(D)xylo-pentoaldofuranose 
• 163396-30-3 2’,3’,5’-O-tribenzyl-D-xylonic acid-1’,4’-lactone 
• 892858-75-2 methyl 2-O-benzyl-D-xylofuranoside 
• 51755-00-1 methyl 3-O-benzyl-3,5-O-isopropylidene-α-D-xylofuranoside 
• 7045-40-1 Methyl 3,5-O-Isopropylidene-α-D-xylofuranoside 
• 1824-96-0 methyl α-D-xylofuranoside 
• 100-39-0 benzyl bromide 
• 20031-21-4 1,2-O-isopropylidene-α-D-xylose 
• 41341-99-5 3,5-di-O-benzyl-1,2-O-isopropylidene-α-D-xylofuranose 
• 1824-96-0 methyl xylofuranoside 
• 87-72-9 D-Xylose 
• 197716-38-4 2,3,5-tri-O-benzyl-1-O-methyl-D-xylofuranoside 
• 79083-40-2 2,3,5-tri-O-benzyl-1-O-methyl-α-D-xylofuranoside 

Downstream Products

• 197716-45-3 3-Oxo-octanoic acid (S)-2-hydroxy-2-((4R,5R)-5-methoxymethoxy-2-phenyl-[1,3]dioxan-4-yl)-ethyl ester 
• 197716-46-4 3-Hexanoyl-4-((4R,5R)-5-methoxymethoxy-2-phenyl-[1,3]dioxan-4-yl)-5H-furan-2-one 
• 197716-43-1 3-Oxo-octanoic acid (2S,3R,4R)-2,3,5-tris-benzyloxy-4-methoxymethoxy-pentyl ester 
• 197716-41-9 tert-Butyl-diphenyl-((2S,3R,4R)-2,3,5-tris-benzyloxy-4-methoxymethoxy-pentyloxy)-silane 
• 126264-87-7 2,3,5-tri-O-benzyl-1,4-dideoxy-1,4-imino-N-benzyl-L-arabinitol 
• 1426550-08-4 pentyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-imino-L-idohexonamide 
• 1426550-07-3 pentyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-imino-L-gulohexonamide 
• 1426550-06-2 1,1,3,3-tetramethylbutyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-imino-L-idohexonamide 
• 1426550-05-1 1,1,3,3-tetramethylbutyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-imino-L-gulohexonamide 
• 1426550-04-0 5-(adamantan-1-yl-methoxy)pentyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-imino-L-idohexonamide 
• 1426550-03-9 5-(adamantan-1-yl-methoxy)pentyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-imino-L-gulohexonamide 
• 1426550-02-8 pentyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-(pent-4-enimido)-L-idohexonamide 
• 1426550-01-7 pentyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-(pent-4-enimido)-L-gulohexonamide 
• 1426550-00-6 1,1,3,3-tetramethylbutyl 3,4,6-tri-O-benzyl-2,5-dideoxy-2,5-(pent-4-enimido)-L-idohexonamide 

Relevant articles and documents

Synthesis and Evaluation of Hybrid Structures Composed of Two Glucosylceramide Synthase Inhibitors

Glucosylceramide metabolism and the enzymes involved have attracted significant interest in medicinal chemistry, because aberrations in the levels of glycolipids that are derived from glucosylceramide are causative in a range of human diseases including lysosomal storage disorders, type2 diabetes, and neurodegenerative diseases. Selective modulation of one of the glycoprocessing enzymes involved in glucosylceramide metabolism - glucosylceramide synthase (GCS), acid glucosylceramidase (GBA1), or neutral glucosylceramidase (GBA2) - is therefore an attractive research objective. In this study we took two established GCS inhibitors, one based on deoxynojirimycin and the other a ceramide analogue, and merged characteristic features to obtain hybrid compounds. The resulting 39-compound library does not contain new GCS inhibitors; however, a potent (200nm) GBA1 inhibitor was identified that has little activity toward GBA2 and might therefore serve as a lead for further biomedical development as a selective GBA1 modulator. Taking the best of both: Two established glucosylceramide synthase (GCS) inhibitors were merged via convergent synthesis to obtain hybrid compounds. Members of this 39-compound library have characteristics of both parent GCS inhibitors. No new GCS inhibitors were established, but a potent (200nm) acid glucosylceramidase (GBA1) inhibitor was identified. This adamantanemethyloxypenanoic acid pyrrolidene-substituted derivative of eliglustat can serve as a lead for further biomedical development of selective GBA1 modulators.

GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME

The compounds of the present invention relate to chain-extended and chain-modified analogues of salacinol, including embodiments where the sulfate moiety has been substituted with a carboxylate or phosphate moiety. In other embodiments the sulfate moiety has been shifted by one carbon atom in the zwitterionic structure. In another embodiment the polyhydroxylated side chain may be replaced with a lipophilic alkyl chain and a suitable counterion. The invention also encompasses methods for synthesizing the salacinol analogues and using the analogues for enzyme inhibition applications.

Formal synthesis of (-)-syringolide 1 starting from D-xylose based on a biomimetic strategy

An expeditious and practical synthertic process for a nonproteinaceous elicitor, (-)-syringolide 1, has been developed in a short number of steps utilizing the putative biosynthetic pathway by featuring the elaboration of the protected D-xylose as a starting material.